Is AZN or BUD cheaper?

On trailing earnings, BUD is cheaper: AZN trades at a 26.92 P/E and BUD at 13.57.

Which has grown faster, AZN or BUD?

Over the past five years, AZN grew revenue faster — AZN at a 16.99% CAGR versus BUD at 3.94%.

Does AZN or BUD pay a bigger dividend?

AZN yields 1.79% and BUD yields 1.63% based on trailing dividends and the latest price.

Is AZN or BUD more profitable?

AZN runs the higher net margin — AZN at 17.19% versus BUD at 10.14%.

Which has been the better investment, AZN or BUD?

Over the past 10-year, AZN delivered the higher annualized total return — AZN at 15.77% versus BUD at -2.09%. Past performance doesn't predict future results.

AstraZeneca PLC (AZN) vs Anheuser-Busch InBev SA/NV (BUD)

AZN leads on 10 of 17 compared metrics, though BUD is the cheaper stock.

A side-by-side comparison of AstraZeneca PLC and Anheuser-Busch InBev SA/NV across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of June 15, 2026. The ● marks the stronger figure on each row (cheaper multiple, higher margin/return).

Anheuser-Busch InBev SA/NV

$160.41B

$82.91Consumer Defensive

Total return — AZN vs BUD

growth of $100 · last 17y

AZN +300.5%BUD +115.4%AZN compounded faster

AZN BUD

AZN vs BUD: by the numbers

•AZN is the larger company ($277.22B vs $160.41B market cap).
•BUD trades at the lower earnings multiple (13.57 vs 26.92 P/E).
•AZN converts more revenue to profit (17.19% vs 10.14% net margin).
•AZN grew revenue faster over the past five years (16.99% vs 3.94% CAGR).
•AZN pays the higher dividend yield (1.79% vs 1.63%).

Which is better, AZN or BUD?

Metric tally: AZN 10 · BUD 7

It depends on what you're optimizing for:

ValueBUD(lower P/E)

GrowthAZN(faster 5Y revenue CAGR)

IncomeAZN(higher dividend yield)

QualityAZN(higher ROIC)

Metrics side by side

Valuation

Metric	AZN	BUD
P/E ratio	26.92	13.57●
Forward P/E	15.33●	17.10
P/S ratio	4.62	1.36●
P/B ratio	5.90	1.88●
PEG ratio	0.14●	1.00
EV / EBITDA	14.92	6.41●
FCF yield	2.89%	13.64%●

Profitability

Metric	AZN	BUD
Gross margin	81.68%●	55.67%
Operating margin	23.69%	31.82%●
Net margin	17.19%●	10.14%
ROE	21.95%●	13.99%
ROIC	13.03%●	6.32%

Dividends

Metric	AZN	BUD
Dividend yield	1.79%●	1.63%
Payout ratio	48.48%	38.95%

Growth (annualized)

Metric	AZN	BUD
Revenue CAGR (5Y)	16.99%●	3.94%
EPS CAGR (5Y)	22.02%	37.66%●
FCF CAGR (5Y)	15.68%●	10.48%
Total return CAGR (5Y)	11.03%●	2.64%

Frequently asked

Which is better, AZN or BUD?: It depends on your goal. value: BUD (lower P/E); growth: AZN (faster 5Y revenue CAGR); income: AZN (higher dividend yield); quality: AZN (higher ROIC). Across all compared metrics, AZN leads 10 to 7.
Is AZN or BUD cheaper?: On trailing earnings, BUD is cheaper: AZN trades at a 26.92 P/E and BUD at 13.57.
Which has grown faster, AZN or BUD?: Over the past five years, AZN grew revenue faster — AZN at a 16.99% CAGR versus BUD at 3.94%.
Does AZN or BUD pay a bigger dividend?: AZN yields 1.79% and BUD yields 1.63% based on trailing dividends and the latest price.
Is AZN or BUD more profitable?: AZN runs the higher net margin — AZN at 17.19% versus BUD at 10.14%.
Which has been the better investment, AZN or BUD?: Over the past 10-year, AZN delivered the higher annualized total return — AZN at 15.77% versus BUD at -2.09%. Past performance doesn't predict future results.

Go deeper

Full AZN analysis Full BUD analysis Interactive comparison tool

Dig into the metrics

AstraZeneca P/E ratio Anheuser-Busch InBev SA/NV P/E ratio AstraZeneca dividend yield Anheuser-Busch InBev SA/NV dividend yield AstraZeneca ROE Anheuser-Busch InBev SA/NV ROE AstraZeneca operating margin Anheuser-Busch InBev SA/NV operating margin AstraZeneca revenue growth Anheuser-Busch InBev SA/NV revenue growth AstraZeneca free cash flow Anheuser-Busch InBev SA/NV free cash flow

AstraZeneca & Anheuser-Busch InBev SA/NV appear in these rankings

Fastest Revenue Growth Stocks Highest Operating Margin Stocks Highest FCF Yield Stocks Best 10-Year Total Return Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified June 15, 2026.